Effects of Mediterranean Diet, Curcumin, and Resveratrol on Mild-to-Moderate Active Ulcerative Colitis: A Multicenter Randomized Clinical Trial

被引:3
|
作者
Dogan, Ozge Erol [1 ,2 ]
Celik, Kezban Esen Karaca [3 ]
Bas, Murat [3 ]
Alan, Eyup Hakan [4 ]
Cagin, Yasir Furkan [5 ]
机构
[1] Acibadem Mehmet Ali Aydinlar Univ, Inst Hlth Sci, Dept Nutr & Dietet, TR-34752 Istanbul, Turkiye
[2] Ardahan Univ, Vocat Sch Hlth Serv, Dept Hlth Care Serv, TR-75002 Ardahan, Turkiye
[3] Acibadem Mehmet Ali Aydinlar Univ, Dept Nutr & Dietet, Fac Hlth Sci, TR-34752 Istanbul, Turkiye
[4] Malatya Training & Res Hosp, Dept Gastroenterol, TR-44330 Malatya, Turkiye
[5] Inonu Univ, Fac Med, Dept Gastroenterol, TR-44280 Malatya, Turkiye
关键词
ulcerative colitis; Mediterranean diet; curcumin; resveratrol; supplementation; inflammatory bowel diseases; INFLAMMATORY BOWEL DISEASES; QUALITY-OF-LIFE; DOUBLE-BLIND; WEIGHT-LOSS; METAANALYSIS; SUPPLEMENTATION; THERAPY; INDEXES; PATIENT; RISK;
D O I
10.3390/nu16101504
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
This study aimed to investigate the effects of the Mediterranean diet (MD), combined with curcumin and resveratrol supplementation, on disease activity, serum inflammatory markers, and quality of life in patients with mild-to-moderate active ulcerative colitis (UC). This study was designed as a prospective multicenter three-arm randomized controlled trial. Participants were randomized to the MD, MD + curcumin, and MD + resveratrol groups. All participants were placed on the MD for 8 weeks. The MD + curcumin group also received 1600 mg/day of curcumin supplementation, whereas the MD + resveratrol group received 500 mg/day of resveratrol supplementation for 8 weeks. Anthropometric measurements, Truelove-Witts Index, Short Form-36, Inflammatory Bowel Disease Questionnaire, Mediterranean Diet Adherence Scale (MEDAS), and laboratory tests were performed at baseline and postintervention. Within-group comparisons showed that MD, MD + curcumin, and MD + resveratrol interventions were effective in reducing disease activity and inflammation and improving quality of life in individuals with UC (p < 0.05). Between-group comparisons revealed no significant difference in all parameters except for the pain subparameter of SF-36 and the MEDAS score (p < 0.05). The MD is an effective and safe intervention to be used in clinical practice in individuals with UC.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial
    Lang, Alon
    Salomon, Nir
    Wu, Justin C. Y.
    Kopylov, Uri
    Lahat, Adi
    Har-Noy, Ofir
    Ching, Jessica Y. L.
    Cheong, Pui Kuan
    Avidan, Benjamin
    Gamus, Dorit
    Kaimakliotis, Ioannis
    Eliakim, Rami
    Ng, Siew C.
    Ben-Horin, Shomron
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (08) : 1444 - +
  • [2] Tripeptide K(D)PT Is Well Tolerated in Mild-to-moderate Ulcerative Colitis: Results from a Randomized Multicenter Study
    Kucharzik, Torsten
    Lemmnitz, Gunter
    Abels, Christoph
    Maaser, Christian
    INFLAMMATORY BOWEL DISEASES, 2017, 23 (02) : 261 - 271
  • [3] Novel Bioenhanced Curcumin With Mesalamine for Induction of Clinical and Endoscopic Remission in Mild-to-Moderate Ulcerative Colitis A Randomized Double-Blind Placebo-controlled Pilot Study
    Banerjee, Rupa
    Pal, Partha
    Penmetsa, Amulya
    Kathi, Pradip
    Girish, Ganesh
    Goren, Idan
    Reddy, D. Nageshwar
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2021, 55 (08) : 702 - 708
  • [4] Dietary adherence to the Mediterranean diet pattern in a randomized clinical trial of patients with quiescent ulcerative colitis
    Haskey, Natasha
    Shim, Rachel C. K.
    Davidson-Hunt, Alexander
    Ye, Jiayu
    Singh, Sunny
    Dieleman, Levinus A.
    Jacobson, Kevan
    Ghosh, Sanjoy
    Gibson, Deanna L.
    FRONTIERS IN NUTRITION, 2022, 9
  • [5] Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis - A randomized, placebo-controlled, pilot study
    Singla, Vikas
    Mouli, Venigalla Pratap
    Garg, Sushil Kumar
    Rai, Tarun
    Choudhury, Bikash Narayan
    Vernna, Prashant
    Deb, Rachana
    Tiwari, Veena
    Rohatgi, Sarika
    Dhingra, Rajan
    Kedia, Saurabh
    Sharma, Piyush Kumar
    Makharia, Govind
    Ahuja, Vineet
    JOURNAL OF CROHNS & COLITIS, 2014, 8 (03) : 208 - 214
  • [6] Combined Diosmectite and Mesalazine Treatment for Mild-to-Moderate Ulcerative Colitis: A Randomized, Placebo-Controlled Study
    Jiang, Xue-Liang
    Wang, Hua-Hong
    Cui, Hui-Fei
    MEDICAL SCIENCE MONITOR, 2015, 21 : 163 - 170
  • [7] Safety, Efficacy, and Pharmacokinetics of Balsalazide in Pediatric Patients With Mild-to-Moderate Active Ulcerative Colitis: Results of a Randomized, Double-blind Study
    Quiros, J. Antonio
    Heyman, Melvin B.
    Pohl, John F.
    Attard, Thomas M.
    Pieniaszek, Henry J.
    Bortey, Enoch
    Walker, Kelli
    Forbes, William P.
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2009, 49 (05) : 571 - 579
  • [8] Randomized Controlled Clinical Trials in Mild-Moderate Ulcerative Colitis
    Cappello, Maria
    Randazzo, Claudia
    Bravat, Ivana
    REVIEWS ON RECENT CLINICAL TRIALS, 2012, 7 (04) : 256 - 269
  • [9] Efficacy and safety of fecal microbiota transplantation via colonoscopy as add-on therapy in patients with mild-to-moderate ulcerative colitis: A randomized clinical trial
    Tkach, Sergii
    Dorofeyev, Andrii
    Kuzenko, Iurii
    Falalyeyeva, Tetyana
    Tsyryuk, Olena
    Kovalchuk, Oleksandr
    Kobyliak, Nazarii
    Abenavoli, Ludovico
    Boccuto, Luigi
    FRONTIERS IN MEDICINE, 2023, 9
  • [10] Randomized clinical trial: Atorvastatin versus placebo in patients with acute exacerbation of mild to moderate ulcerative colitis
    Dhamija P.
    Hota D.
    Kochhar R.
    Sachdev A.
    Chakrabarti A.
    Indian Journal of Gastroenterology, 2014, 33 (2) : 151 - 156